Health ❯ Healthcare ❯ Chronic Diseases

Diabetes

Type 2 Diabetes Obesity Management Strategies Type 1 Diabetes Diabetes Management Heart Disease Insulin Therapy GLP-1 Receptor Agonists Treatment Options Semaglutide

3 ARTICLES

last wk.

Study: GLP‑1 Use Soared and Shifted Costs From Patients to Insurers and Taxpayers

A July study shows rapid uptake drove big jumps in total spending even as patient out‑of‑pocket payments fell, creating fresh questions about who pays for long‑term use.

7 ARTICLES

last wk.

Study Finds Small Increase in Optic‑Nerve Injury With GLP‑1 Diabetes Drugs

4 ARTICLES

3w ago

Large Penn Study Finds GLP‑1 Use Tied to Lower Breast Cancer Rates

5 ARTICLES

4w ago

Study Finds Small Rise in Smell and Taste Diagnoses Among People on GLP‑1 Diabetes Drugs

8 ARTICLES

last mo.

New Data Show Lower Activity, Muscle Loss and Mood Changes Linked to GLP‑1 Weight Drugs

16 ARTICLES

last mo.

Wearable Data Show People Move Less After Starting GLP‑1 Weight‑Loss Drugs

7 ARTICLES

last mo.

Major U.S. Societies Publish First Clinical Guideline for Cardiovascular‑Kidney‑Metabolic Syndrome

4 ARTICLES

last mo.

CagriSema Combo Lowers Blood Sugar and Drives Bigger Weight Loss Than Semaglutide Alone

3 ARTICLES

last mo.

Study Shows Medically Tailored Meals Cut Hospitalizations 31% and Nearly Pay for Themselves

4 ARTICLES

last mo.

Report Finds Peru Delivers Complete Medicines for Fewer Than Half of SIS Prescriptions

3 ARTICLES

2mo ago

New Data Link GLP-1 Weight-Loss Drugs to Fewer Sick Days and Lower Disease Risks

4 ARTICLES

2mo ago

AIIMS Delhi Performs First Pancreas–Kidney Transplant in 18 Years

7 ARTICLES

2mo ago

AOK Data Show Heart Attack Rates Falling in Bavaria and Mecklenburg-Vorpommern

5 ARTICLES

2mo ago

Health Canada Approves Apotex’s Generic Ozempic, Opening Canada’s Market to Lower-Cost Semaglutide

8 ARTICLES

3mo ago

Mexico’s 50+ Population Reaches 32 Million as Diabetes and Hypertension Rise, Reported Access Falls

3 ARTICLES

3mo ago

ACLM Releases ‘Project Remission’ Film Series on Lifestyle Treatment for Type 2 Diabetes

Diabetes

Study: GLP‑1 Use Soared and Shifted Costs From Patients to Insurers and Taxpayers

Study Finds Small Increase in Optic‑Nerve Injury With GLP‑1 Diabetes Drugs

Large Penn Study Finds GLP‑1 Use Tied to Lower Breast Cancer Rates

Study Finds Small Rise in Smell and Taste Diagnoses Among People on GLP‑1 Diabetes Drugs

New Data Show Lower Activity, Muscle Loss and Mood Changes Linked to GLP‑1 Weight Drugs

Wearable Data Show People Move Less After Starting GLP‑1 Weight‑Loss Drugs

Major U.S. Societies Publish First Clinical Guideline for Cardiovascular‑Kidney‑Metabolic Syndrome

CagriSema Combo Lowers Blood Sugar and Drives Bigger Weight Loss Than Semaglutide Alone

Study Shows Medically Tailored Meals Cut Hospitalizations 31% and Nearly Pay for Themselves

Report Finds Peru Delivers Complete Medicines for Fewer Than Half of SIS Prescriptions

Never miss stories about

Diabetes

New Data Link GLP-1 Weight-Loss Drugs to Fewer Sick Days and Lower Disease Risks

AIIMS Delhi Performs First Pancreas–Kidney Transplant in 18 Years

AOK Data Show Heart Attack Rates Falling in Bavaria and Mecklenburg-Vorpommern

Health Canada Approves Apotex’s Generic Ozempic, Opening Canada’s Market to Lower-Cost Semaglutide

Novo Nordisk’s Oral Semaglutide Lowers HbA1c in Teens in Pivotal Trial

VDR Gene Variant Tied to 19% Lower Diabetes Risk With High-Dose Vitamin D3

Anvisa Approves Mounjaro for Type 2 Diabetes in Children Ages 10–17

India’s Generic Semaglutide Wave Eats Into Mounjaro’s Lead as Novo Holds Share

Mexico’s 50+ Population Reaches 32 Million as Diabetes and Hypertension Rise, Reported Access Falls

ACLM Releases ‘Project Remission’ Film Series on Lifestyle Treatment for Type 2 Diabetes

Never miss stories about

Diabetes